Dr Lal PathLabs Selects Qritive’s AI-Powered Solution to Strengthen Cancer Diagnostics

Singapore, Aug 21, 2025 — Qritive is proud to announce that Dr Lal PathLabs, one of India’s leading diagnostic providers, has selected QAi Lymph Node Dx to enhance its capabilities in detecting lymph node metastasis as part of routine clinical workflows. 

Through this deployment, QAi Lymph Node Dx will support pathologists in identifying metastases — including micrometastases — across a wide range of cancer types, helping deliver faster and more accurate diagnostic insights. 

With the increasing complexity and workload in oncology diagnostics, there is a growing need for scalable tools that improve efficiency and precision. Lymph node evaluation, particularly for micrometastases, is a high-stakes and time-intensive task. QAi Lymph Node Dx addresses this challenge by identifying both macro- and micrometastatic deposits with high sensitivity and speed. 

“Our goal is to enable real-world clinical environments with robust, validated AI that integrates seamlessly into existing workflows. We are proud to support Dr Lal PathLabs — a pioneer in diagnostic innovation — as they set new standards for precision in cancer care in India.”  — Bruno Occhipinti, CEO, Qritive

According to Dr Lal PathLabs, the solution demonstrated complete sensitivity and zero false negatives, as validated through immunohistochemistry. QAi Lymph Node Dx has also been validated across multiple cancer types, including breast, colon, and gastric cancer, ensuring flexible application in varied clinical settings. 

“The role of a pathologist is evolving rapidly, and we must evolve with it. Introducing AI into our diagnostic workflow is not just about adopting technology — it’s about reimagining how we detect and respond to disease.”  — Dr Vandana Lal, Executive Director, Dr Lal PathLabs

As part of the validation journey, these findings were also featured in a co-study at USCAP 2025, one of the world’s leading pathology congresses, highlighting QAi Lymph Node Dx’s ability to detect metastases with confidence and reproducibility. 

This adoption further reinforces Qritive’s vision to deliver scalable, validated AI solutions that meet the needs of real-world clinical practice. 

About Qritive

Headquartered in Singapore, with operations in the US and India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes. Qritive leverages deep learning technology to support the interpretation of pathology tests for time and resource-strapped pathologists, enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance. 

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com